Abstract | BACKGROUND: METHODS: Retrospective observational cohort study, based on multicenter computerized medical charts of pediatric patients with idiopathic intracranial hypertension diagnosed between 2007-2018 in three medical centers serving one metropolitan area (an estimated population of 400,000 children). Clinical and laboratory data of children up to 18 years old, fulfilling the Friedman criteria and taking acetazolamide, were collected and analyzed. RESULTS: Sixty-eight patients were included with a mean acetazolamide treatment duration of 8.5 months and a median maximal dose 18 mg/kg/d. Sixty-two children had mild (76%), moderate (13%), or severe (1.5%) metabolic acidosis. At least one adverse effect (neurologic, gastrointestinal, renal) was recorded among 27% of patients. No significant difference was found between the mean pH of children with or without clinical adverse effects (p = 0.35). No correlation was found between laboratory acidosis and adverse effect severity (p = 0.3), or between median acetazolamide dose and acidosis level (p = 0.57). CONCLUSIONS:
|
Authors | Yarden Bulkowstein, Adi Nitzan-Luques, Aviad Schnapp, Noa Barnoy, Shimon Reif, Tal Gilboa, Oded Volovesky |
Journal | Pediatric nephrology (Berlin, Germany)
(Pediatr Nephrol)
Vol. 39
Issue 1
Pg. 185-191
(Jan 2024)
ISSN: 1432-198X [Electronic] Germany |
PMID | 37480382
(Publication Type: Observational Study, Multicenter Study, Journal Article)
|
Copyright | © 2023. The Author(s), under exclusive licence to International Pediatric Nephrology Association. |
Chemical References |
- Acetazolamide
- Carbonic Anhydrase Inhibitors
|
Topics |
- Humans
- Child
- Acetazolamide
(adverse effects)
- Pseudotumor Cerebri
(drug therapy, diagnosis)
- Carbonic Anhydrase Inhibitors
(adverse effects)
- Retrospective Studies
- Acidosis
(chemically induced, drug therapy)
|